Showing results (1-10 of 128) with videos related to
Sort By:
Pageof 13
Current Radiopharmaceuticals|December 29, 2011
The ARRONAX projectFerid Haddad, Jacques Barbet, Jean-Francois ChatalJournal of Cancer Research and Therapeutics|December 17, 2009
Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumorsJean-Francois Chatal, Francois Davodeau, Michel Cherel, et al.Update on Cancer Therapeutics|March 4, 2008
Cancer Imaging and Therapy with Bispecific Antibody PretargetingDavid M Goldenberg, Jean-Francois Chatal, Jacques Barbet, et al.Frontiers in Oncology|June 27, 2013
Improvement of radioimmunotherapy using pretargetingEric Frampas, Caroline Rousseau, Caroline Bodet-Milin, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell linesStephane Supiot, Sebastien Gouard, Josiane Charrier, et al.European Journal of Nuclear Medicine and Molecular Imaging|May 10, 2008
ARRONAX, a high-energy and high-intensity cyclotron for nuclear medicineFerid Haddad, Ludovic Ferrer, Arnaud Guertin, et al.International Journal of Molecular Sciences|December 31, 2016
Immuno-PET for Clinical Theranostic ApproachesClément Bailly, Pierre-François Cléry, Alain Faivre-Chauvet, et al.Frontiers in Medicine|August 12, 2022
How Efficient Are Monte Carlo Calculations Together With the Q-System to Determine Radioactive Transport Limits? Case Study on Medical RadionuclidesMaddalena Maietta, Ferid Haddad, Sebastien AvilaPharmaceutical Statistics|April 13, 2019
Equilibrium, affinity, dissociation constants, IC5O: Facts and fantasiesJacques Barbet, Sandrine Huclier-MarkaiInternational Journal of Molecular Sciences|February 14, 2015
Tumor immunotargeting using innovative radionuclidesFrançoise Kraeber-Bodéré, Caroline Rousseau, Caroline Bodet-Milin, et al.Pageof 13